Ambrosia Biosciences
Drug-discovery company developing oral small-molecule treatments for obesity and metabolic disorders.
$100MSeries B
LeadDT
Deep Track Capital
Activity from announced rounds
Activity in this selectionOct 24, 2026 · Healthtech · Jan 1, 2026
Deep Track Capital is a life-sciences investor identified by Draig Therapeutics and Superluminal Medicines.
Recorded funding activity
Superluminal combines structural biology, protein dynamics, machine learning and experiments to discover small-molecule medicines. Draig develops neuropsychiatric treatments, while Triveni works on antibodies for immunological and inflammatory disorders. These company relationships give context to the recorded financings.
- Rounds participated in
- 1
- Confirmed lead rounds
- 1 All roles disclosed
- New companies
- 1 First participation on record · 0 follow-on
- Funding in participating rounds
- $100M 1 disclosed · full round size, not this investor’s share